新闻/Reuters/Pharmaessentia Announces Positive Topline Phase 2B Data From Exceed-Et Study Evaluating Ropeginterferon Alfa-2B-Njft For Essential Thro…Pharmaessentia Announces Positive Topline Phase 2B Data From Exceed-Et Study Evaluating Ropeginterferon Alfa-2B-Njft For Essential Thrombocythemia阅读全文在TradingView,您可以无限访问来自Reuters和所有其他新闻来源的文章。继续阅读